Maverick Pharma Profile
Key Indicators
- Authorised Capital ₹ 2.00 M
- Paid Up Capital ₹ 2.00 M
- Company Age 21 Year, 4 Months
- Last Filing with ROC 31 Mar 2024
- Revenue Growth -4.13%
- Profit Growth 4.73%
- Ebitda -5.20%
- Net Worth 14.19%
- Total Assets 9.90%
About Maverick Pharma
Maverick Pharma Private Limited (MPPL) is a Private Limited Indian Non-Government Company incorporated in India on 25 September 2003 and has a history of 21 years and four months. Its registered office is in Delhi, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 2.00 M and a paid-up capital of Rs 2.00 M, as per Ministry of Corporate Affairs (MCA) records.
Akhil Gupta, Rajesh Garg, and Vikas Singla serve as directors at the Company.
Company Details
-
Location
Delhi, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U24246DL2003PTC122403
-
Company No.
122403
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
25 Sep 2003
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Delhi
Industry
What products or services does Maverick Pharma Private Limited offer?
Maverick Pharma Private Limited offers a wide range of products and services, including Health Conditions, Bone, Joint & Muscle Care.
Who are the key members and board of directors at Maverick Pharma?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Akhil Gupta
|
Director | 18-Feb-2006 | Current |
|
Rajesh Garg
|
Director | 25-Sep-2003 | Current |
|
Vikas Singla
|
Director | 25-Sep-2003 | Current |
Financial Performance of Maverick Pharma.
Maverick Pharma Private Limited, for the financial year ended 2020, experienced Minor drop in revenue, with a 4.13% decrease. The company also saw a slight improvement in profitability, with a 4.73% increase in profit. The company's net worth Soared by an impressive increase of 14.19%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Maverick Pharma?
In 2020, Maverick Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Maxy Share Services LimitedVikas Singla is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Maverick Pharma?
Unlock and access historical data on people associated with Maverick Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Maverick Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Maverick Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
